Trial reportBMC anesthesiology2026
Effect of ciprofol with etomidate on the occurrence of hypotension in elderly patients undergoing upper gastrointestinal endoscopy: a prospective randomized controlled study.
Trial report in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCiprofol is increasingly used for endoscopic sedation due to its reduced injection pain, but evidence regarding its safety when combined with etomidate in elderly patients remains limited. This study evaluated the efficacy and safety of ciprofol–etomidate compared with ciprofol alone and propofol–etomidate in elderly patients undergoing upper gastrointestinal endoscopy.
methodsIn this randomized controlled trial, 402 patients aged ≥ 60 years scheduled for upper gastrointestinal endoscopy were assigned to one of three groups: ciprofol–etomidate (EC: 0.3 mg/kg ciprofol + 0.12 mg/kg etomidate), ciprofol (C: 0.4 mg/kg) alone, or propofol–etomidate (EP: 1.2 mg/kg propofol + 0.12 mg/kg etomidate). All patients received remifentanil 0.3 µg/kg before sedation. The primary outcome was hypotension incidence. Secondary outcomes included sedation success, vital signs, and other adverse events.
resultsHypotension incidence differed significantly among groups (EC: 64.5%, C: 80.9%, EP: 75.2%; p = 0.008), with a lower rate in the EC group versus the C group (p = 0.003). Injection pain was rare in both EC (0.7%) and C (1.5%) groups compared with EP (9.0%; p < 0.001). Induction time was longer in EC and C groups than in EP. Recovery and discharge times were prolonged in the C group compared with EP. Other adverse events, including bradycardia, hypoxemia, nausea, vomiting, dizziness, and tremors, did not differ significantly among groups.
conclusionsThe combination of ciprofol and etomidate offers effective sedation, reducing hypotension compared with ciprofol alone and injection pain compared with propofol–etomidate, and may therefore represent a safer alternative for elderly patients undergoing upper gastrointestinal endoscopy.
trial registrationChinese Clinical Trial Registry, ChiCTR2300077770 (date: 20/11/2023).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.